Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs XPO Inc. Common Stock (XPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs XPO Inc. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while XPO Inc. Common Stock trades at $187.74 (market cap $21.21B). The key difference: XPO Inc. Common Stock is far larger — about 2.4× Kymera Therapeutics Inc. Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, XPO Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and XPO Inc. Common Stock for 6 Days on average.
| KYMR | XPO | |
|---|---|---|
Market Cap | $8.87B | $21.21B |
Volume | 779,107 | 663,957 |
Sector | Health | Industrials |
52-Week High | $127.31 | $228.37 |
52-Week Low | $55.80 | $123.66 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.26B | $24.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XPO trades at $181.15, up 0.35% today, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $8.6B in 2026, and net income margin improved to 4.71%. Recent news highlights operational expansions and industry recognition, such as new service centers and a FreightTech 100 award.
The outlook is positive with strong analyst support—71.9% recommend Buy and a consensus price target of $227.64 implies ~26% upside. Key risks include high valuation multiples (P/E 53.44) and exposure to freight market volatility. Earnings growth and margin improvements are primary catalysts, but investors should monitor competitive pressures and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About XPO Inc. Common Stock
XPO provides freight transportation services in North America and Europe. Its operations include less-than-truckload freight transportation and brokerage services supported by a technology platform.
Read more on XPO →
